France's ANSES Issues Guidance on Sports Supplement Safety

Paris, France — 08 June 2026

France's Agency for Food, Environmental and Occupational Health & Safety (ANSES) has formally issued an opinion, dated 13 May 2026, stemming from its Nutrivigilance programme. The opinion, under reference NUT-2025-VIG-0110, specifically addresses health risks associated with certain sports nutrition products and ingredients. Key concerns highlighted include risks of liver decompensation, acute hepatitis, acute renal failure, and effects on transplanted organs, linked to specific compounds within these supplements. Ingredients under scrutiny include specific formulations of Vitamin B3, Vitamin A, and certain whey protein preparations.

The Nutrivigilance initiative tracks adverse health events related to food supplements, providing critical data for consumer protection. This latest opinion underscores the agency's proactive stance in identifying and mitigating risks within the rapidly expanding sports nutrition sector. The focus on high-dose vitamins and protein types indicates a targeted effort to refine safety profiles for widely used supplement categories. Manufacturers should note the explicit mention of 'Produits pour sportif' (sports products) as a key area of concern within the document's keywords, reinforcing the specific market segment under review.

While the full details of the specific vitamin concentrations or whey protein characteristics are not immediately public, the general warning signals a shift towards stricter enforcement and potentially revised guidance on maximum permitted levels for these ingredients in France. This proactive regulatory move by ANSES indicates an intention to prevent serious health incidents, which often lead to extensive product recalls and damage brand reputation. Companies operating within the French market or exporting into it must now consider these warnings as a foundational element of their product safety and compliance strategies.

What this means for France

French manufacturers and brand owners must immediately initiate internal reviews of all sports nutrition product portfolios, prioritising formulations containing Vitamin B3, Vitamin A, and whey proteins, especially those associated with high-dose or specific processing methods. Non-compliance could result in market withdrawals or significant financial penalties. This heightened regulatory focus creates an opportunity for brands to differentiate through transparent sourcing and robust safety data. Procurement teams should anticipate increased demand for accredited ingredient suppliers capable of providing comprehensive safety dossiers. Competitive advantage will lie with companies that can swiftly adapt product lines to meet evolving safety standards and demonstrate proactive risk management.

The impact of this ANSES opinion extends to product innovation and marketing claims. Future product development cycles must integrate these safety considerations at the earliest stages, potentially necessitating reformulation windows of 6-12 months for affected products. Retailers stocking sports supplements in France are also advised to prepare for potential increased consumer inquiries regarding product safety and ingredient origins, demanding greater transparency from their suppliers. This regulatory tightening reflects a broader European trend towards enhanced food supplement oversight post-Brexit.

For more on UK formulation and manufacturing best practice, learn more at Supplement Factory.